[ad_1]
For the British Health Minister, this is not a setback. The Chinese CanSino defends its vaccine from the doubts of experts outside the company
For the British Health Minister, this is not a setback. The Chinese CanSino defends its vaccine from the doubts of experts outside the company
2 ‘reading
AstraZeneca has stopped clinical trials of the Covid vaccine, which is being studied together with the University of Oxford, due to an adverse reaction developed by one of the trial participants. The drug company said in a statement that in a standard review of vaccine trials, a person developed an unexplained illness. The temporary stop is so researchers have time to review the data, while maintaining the integrity of the experiment. The vaccine is one of those in the most advanced study stage, considered among the main candidates for early market entry.
British Health Minister Matt Hancock said AstraZeneca’s decision to suspend coronavirus vaccine trials was “a challenge”, but not necessarily a setback in vaccine development. “Actually, this is not the first time this has happened to the Oxford vaccine,” he responded to the Sky News microphones. When asked if this could slow down the vaccine development process, he said: “Not necessarily, it depends on what they find when they do research.”
The defense of the Chinese CanSino
CanSino Biologics of China fights back after scientists outside the company raised concerns about the efficacy of CanSino’s Ad5-nCoV candidate, which is based on a common cold virus. The concern is that existing antibodies to the common cold virus could undermine Ad5-nCoV.
“Vaccine development is a science based on practice and we should not blindly follow the experts,” Zhu Tao, chief scientific officer, told an investor conference. He added that there have been cases in which vaccines created with methods questioned by experts had obtained regulatory approvals after clinical trials showed them to work.
No evidence has shown that existing antibodies to the common cold can have a major negative impact on Ad5-nCoV’s ability to trigger antibodies against the new coronavirus, Zhu said, citing the results of 128 participants tested with a lower dose of the candidate. . vaccine. Ad5-nCoV, still in its final testing phase, has been approved for use in the Chinese military.
